European Journal of Cancer
Volume 46, Issue 8 , Pages 1344-1351 , May 2010

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

  • Axel Le Cesne

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • Corresponding Author InformationCorresponding author: Oncologie Médicale, Institut Gustave Roussy, 26 rue Camille Desmoulins, 94805 Villejuif, France. Tel.: +33 (0) 1 42 11 43 16; fax: +33 (0) 1 42 11 52 19.
    • ,
  • Jean-Yves Blay

      Affiliations

    • Hôpital Edouard Herriot and INSERM U453, Centre Léon Bérard, Lyon, France
    • ,
  • Binh Nguyen Bui

      Affiliations

    • Institut Bergonié, Bordeaux, France
    • ,
  • Olivier Bouché

      Affiliations

    • CHU Reims, Hôpital Robert Debré, Reims, France
    • ,
  • Antoine Adenis

      Affiliations

    • Centre Oscar Lambret, Lille, France
    • ,
  • Julien Domont

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • Angela Cioffi

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • Isabelle Ray-Coquard

      Affiliations

    • Hôpital Edouard Herriot and INSERM U453, Centre Léon Bérard, Lyon, France
    • ,
  • Nathalie Lassau

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • Sylvie Bonvalot

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • Alain Moussy

      Affiliations

    • AB Science, SA, Paris, France
    • ,
  • Jean-Pierre Kinet

      Affiliations

    • Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    • ,
  • Olivier Hermine

      Affiliations

    • Service d’Hematologie, CNRS, UMR 8147, Centre de référence des mastocytoses, Université Paris V René Descartes, Hôpital Necker, Paris, France

Received 6 November 2009 ,Revised 1 February 2010 ,Accepted 9 February 2010.

References 

  1. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269
  2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  3. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–8121
  4. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003;106:887–895
  5. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710
  6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med. 2002;347:472–480
  7. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134
  8. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–632
  9. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764–4774
  10. Van Glabbeke M, Verweij AM, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study. J Clin Oncol. 2005;23:5795–5803
  11. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer. 2005;41:1751–1757
  12. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  13. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–625
  14. Dubreuil P, Létard S, Ciufolini MA, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258
  15. Soria JC, Massard C, Magne N, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer. 2009;45:2333–2341
  16. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–1103
  17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  18. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433–438
  19. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–1113
  20. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–578
  21. Van Glabbeke M, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts). J Clin Oncol 2007;25(Suppl 18S):10004.
  22. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumor. J Clin Oncol. 2009;27:3141–3147
  23. Van Glabbeke M, Verweij J, Casali PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer. 2006;42:2277–2285
  24. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Therapy. 2009;11:R95
  25. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759
  26. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol. 2006;187:1267–1273
  27. Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–445
  28. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60–5.
  29. Chami L, Lassau N, Koscielny , et al. Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in patients with GIST treated by tyrosine kinase inhibitor (TKI). J Clin Oncol. 2008;26(Suppl):10552
  30. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760–1764
  31. Le Cesne A, van Glabbeke M, Verweij J, et al. Absence of progression as assessed by RECIST predicts survival in advanced gastro-intestinal tumors (GIST) treated with imatinib mesylate: analysis of the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969–3974
  32. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res. 2006;12:3233–3237

☆ Trial registration: Clinicaltrials.gov; NCT00998751; URL: http://clinicaltrials.gov//ct2/show/NCT00998751.

PII: S0959-8049(10)00117-6

doi: 10.1016/j.ejca.2010.02.014

European Journal of Cancer
Volume 46, Issue 8 , Pages 1344-1351 , May 2010

Article Tools

* Image Usage & Resolution